Immunovant (IMVT) Cash from Operations (2019 - 2026)
Immunovant (IMVT) reported Cash from Operations of 95059000.0 for Q1 2026, up 14.08% on a YoY basis from 83326407.98 in Q1 2025, and down 2.96% quarter-over-quarter from 92325000.0 in Q4 2025.
Immunovant (IMVT) Cash from Operations (2019 - 2026) Analysis & Trends
Immunovant has reported Cash from Operations for 8 years, with the latest figure at 95059000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 14.08% year-over-year to 95059000.0; the trailing twelve-month figure through Mar 2026 stood at 407310000.0 (down 8.36% YoY), and the FY2026 full-year result was 407310000.0, down 8.36% from the prior year.
- Cash from Operations for Q1 2026 stood at 95059000.0, down from 92325000.0 in the prior quarter.
- The five-year high for Cash from Operations was 20186000.0 in Q3 2022, with the low at 117411000.0 in Q2 2025.
- Historically, Cash from Operations has averaged 71680000.0 across 5 years, with a median of 65819000.0 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Operations plunged 210.26% — and 2023, when it increased 28.03%.
- Immunovant's Cash from Operations stood at 46395000.0 in 2022, then retreated by 1.52% to 47098000.0 in 2023, then sank by 113.15% to 100391000.0 in 2024, then climbed by 8.03% to 92325000.0 in 2025, then declined by 2.96% to 95059000.0 in 2026.
- The last three Cash from Operations figures came in at 95059000.0 (Q1 2026), 92325000.0 (Q4 2025), and 102515000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Immunovant | 5.71 Bn | 5.71 Bn | - | -95.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -95.06 Mn |
| Mar 31, 2026 | -95.06 Mn |
| Dec 31, 2025 | -92.33 Mn |
| Dec 31, 2025 | -92.33 Mn |
| Sep 30, 2025 | -102.52 Mn |
| Sep 30, 2025 | -102.52 Mn |
| Jun 30, 2025 | -117.41 Mn |
| Jun 30, 2025 | -117.41 Mn |
| Mar 31, 2025 | -110.64 Mn |
| Mar 31, 2025 | -110.64 Mn |
| Dec 31, 2024 | -100.39 Mn |
| Dec 31, 2024 | -100.39 Mn |
| Sep 30, 2024 | -88.65 Mn |
| Sep 30, 2024 | -88.65 Mn |
| Jun 30, 2024 | -76.20 Mn |
| Jun 30, 2024 | -76.20 Mn |
| Mar 31, 2024 | -59.70 Mn |
| Mar 31, 2024 | -59.70 Mn |
| Dec 31, 2023 | -47.10 Mn |
| Dec 31, 2023 | -47.10 Mn |